301 completed, 56 unknown, 42 recruiting, 23 active not recruiting. 138 Phase 1, 121 Phase 2, 58 Not applicable, 58 Phase 3, 10 Phase 4.
Follow Hemorrhagic Fevers, Viral: new trials by email Literature Review of Hemorrhagic Fevers, Viral trials Research Report on Hemorrhagic Fevers, Viral
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind | Phase 1 | Not yet recruiting | VLP Therapeutics | 42 | 2027-01-04 | 2026-09-21 |
| Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers Ervebo, Inmazeb - Ebola Virus Disease | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 132 | 2027-01-01 | 2026-01-22 |
| Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC DECIPHER bioassay - Ebola Hemorrhagic Fever | Not yet recruiting | Institute of Tropical Medicine, Belgium | 100 | 2027-01-01 | 2026-07-07 | |
| Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA FORTIFIEDx and DECIPHER bioassays - Ebola Hemorrhagic Fever, Lassa Hemorrhagic Fever | Not yet recruiting | Institute of Tropical Medicine, Belgium | 150 | 2027-01-01 | 2026-07-02 | |
| Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research Dengue | Not yet recruiting | Liverpool School of Tropical Medicine | 235 | 2026-11-01 | 2026-09-02 | |
| Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo Candidate BDBV vaccine, Active comparator - Ebola Hemorrhagic Fever, Bundibugyo Virus Disease | Phase 2 / Phase 3 | Not yet recruiting | Jean-Pierre Van geertruyden | 3620 | 2026-10-20 | 2026-10-05 |
| Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue | Phase 3 | Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | 8800 | 2026-10-01 | 2026-04-21 |
| A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever Low dose MOPEVAC-Las vaccine, Intermediate dose MOPEVAC-Las vaccine, High dose MOPEVAC-Las vaccine - Lassa Fever | Phase 1 | Recruiting | Institut Pasteur | 72 | 2026-09-28 | 2026-10-13 |
| Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg - Dengue | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 600 | 2026-09-01 | 2026-10-13 |
| EBOla Post-Exposure Prophylaxis Ervebo, Inmazeb - Ebola Virus Disease | Phase 3 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 160 | 2026-09-01 | 2026-01-22 |
| Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants Skin punch biopsy, Blood samples - Yellow Fever (Healthy Volunteers), Biopsy/Methods | Not applicable | Recruiting | Institute of Tropical Medicine, Belgium | 40 | 2026-08-10 | 2026-08-13 |
| Smart Analysis and Decision-Making for Emerging Infectious Diseases Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19 | Not applicable | Enrolling by invitation | Peking University | 108 | 2026-08-10 | 2026-08-19 |
| Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection rDEN2delta30-7169 - Healthy Volunteers, Dengue | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2026-08-07 | 2026-10-22 |
| Gut Leakage' in Dengue Dengue, Dengue Hemorrhagic Fever | Recruiting | University of Oxford | 190 | 2026-08-01 | 2026-08-06 | |
| Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients Exercise - Dengue, Chikungunya | Not applicable | Not yet recruiting | Universidade do Estado do Pará | 54 | 2026-07-01 | 2026-05-26 |
| UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF Favipiravir, Ribavin, Optimised Standard of Care - Crimean-Congo Hemorrhagic Fever | Phase 2 | Recruiting | Liverpool School of Tropical Medicine | 378 | 2026-06-04 | 2026-08-07 |
| Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure ERVEBO® (rVSV∆G-ZEBOV-GP) - Ebola Vaccine | Phase 3 | Withdrawn | Universitätsklinikum Hamburg-Eppendorf | 2026-06-01 | 2026-06-04 | |
| A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health rVSVΔG-SUDV-GP, Placebo - Sudan Virus Disease | Phase 1 | Recruiting | International AIDS Vaccine Initiative | 112 | 2026-05-08 | 2026-09-21 |
| Biomedical Signal Extraction From Symptom Descriptions: An Observational Registry Using the OpenGenome Platform OpenGenome AI Platform - Signs and Symptoms, Fever | Recruiting | OpenGenome | 1000 | 2026-05-05 | 2026-05-19 |
Showing 20 of 483. Sign in to see all of them.
Dengue (275) · Hemorrhagic Fever, Ebola (102) · Severe Dengue (65) · Yellow Fever (44) · Chikungunya Fever (31) · Zika Virus Infection (25) · Virus Diseases (20) · Lassa Fever (19) · Hemorrhagic Fever with Renal Syndrome (14) · Arbovirus Infections (13) · Marburg Virus Disease (12) · Rift Valley Fever (11) · Fever (10) · Malaria (10)
Infections (478) · RNA Virus Infections (477) · Virus Diseases (463) · Vector Borne Diseases (333) · Mosquito-Borne Diseases (329) · Arbovirus Infections (325) · Flaviviridae Infections (321) · Flavivirus Infections (314) · Mononegavirales Infections (114) · Filoviridae Infections (105) · Pathological Conditions, Signs and Symptoms (40) · Togaviridae Infections (32) · Alphavirus Infections (31) · Bunyaviridae Infections (30)
Yellow Fever Vaccine (18) · Dengue Vaccines (14) · Vaccines (14) · Sodium Chloride (11) · Ribavirin (10) · Blood Specimen Collection (9) · Saline Solution (6) · Aluminum Hydroxide (5) · Data Collection (5) · favipiravir (5) · Dexamethasone (4) · Ebola Vaccines (4) · Injections (4) · ansuvimab (4) · atoltivimab, maftivimab, and odesivimab-ebgn drug combination (4)
National Institute of Allergy and Infectious Diseases (NIAID) (63) · Sanofi Pasteur, a Sanofi Company (35) · U.S. Army Medical Research and Development Command (27) · Takeda (17) · University of Oxford (16) · Institute of Tropical Medicine, Belgium (9) · Sanofi (9) · Janssen Vaccines & Prevention B.V. (7) · London School of Hygiene and Tropical Medicine (7) · Mahidol University (7) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (6) · Singapore General Hospital (6) · Butantan Institute (5) · GlaxoSmithKline (5) · Institut Pasteur (5)
United States (132) · Thailand (33) · Brazil (30) · Colombia (22) · Malaysia (20) · Mexico (20) · Singapore (20) · Uganda (16) · Vietnam (16) · France (13) · Germany (13) · Liberia (13) · Philippines (13) · Democratic Republic of the Congo (12) · Kenya (12)
Anna Durbin, MD (26) · Beth Kirkpatrick, MD (4) · Richard T Davey, M.D. (4) · Alison Heald, MD (3) · Deborah Watson-Jones, PhD (3) · Kawsar Talaat, MD (3) · Kristen Pierce, MD (3) · Myrielle Dupont-Rouzeyrol, PhD (3)
PMID 40099800, PMID 42253092, PMID 26214039, PMID 29897841, PMID 33822015, PMID 26383952, PMID 28647166, PMID 39116904, PMID 23563266, PMID 25426834, PMID 25801652, PMID 25830326, PMID 26424605, PMID 26458804, PMID 26546548, PMID 26659569, PMID 27007959, PMID 27418050, PMID 27459266, PMID 28017642, PMID 28871961, PMID 29300876, PMID 30407513, PMID 30855742, PMID 31878895, PMID 31984244, PMID 32220283, PMID 32394880, PMID 32572470, PMID 32932330, PMID 33212068, PMID 33422034, PMID 34003796, PMID 34107180, PMID 34219653, PMID 34930928, PMID 35182042, PMID 35659904, PMID 36057771, PMID 37254133, PMID 37971871, PMID 38294972, PMID 38603720, PMID 39308445, PMID 39356094, PMID 42480195, PMID 10632996, PMID 11009541, PMID 11395204, PMID 14741143
2014 (7), 2019 (5), 2018 (3), 2023 (3), 272201300017C-18-0-1 (2), U19AI057266 (2), 2009 (1), 2015 (1), U01AI141981 (1), U01AI148069 (1), U01AI151799 (1), U44AI145791 (1)